Roche

Swiss multinational healthcare company

For other uses, see Roche (disambiguation).

Roche Holding AG

Roche Tower and Roche Tower 2, headquarters of Hoffmann-La Roche in Basel (2022)

Company type| Public

Traded as

| SIX: RO (voting)
SIX: ROG (non-voting)
ISIN| CH0012032048
Industry| Pharmaceuticals
Predecessor| Hoffmann, Traub & Co. (1894)
Founded| 1 October 1896; 128 years ago (1896-10-01)
Founder| Fritz Hoffmann-La Roche
Headquarters| Basel, Switzerland

Area served

| Worldwide

Key people

* Severin Schwan (chairman)
* André Hoffmann (vice-chairman)
* Thomas Schinecker(CEO)
* Levi Garraway (CMO)[1][2][3]

Products| Pharmaceuticals and diagnostics (List of products)
Revenue|  CHF 62.39 billion (2024)

Operating income

|  CHF 13.42 billion (2024)

Net income

|  CHF 9.19 billion (2024)
Total assets|  CHF 101.80 billion (2024)
Total equity|  CHF 36.16 billion (2024)

Number of employees

|  103,249 (2024)
Subsidiaries|

* Genentech
* Ventana

Website| roche.com
Footnotes / references
[4][5]
Participation certificate of the F. Hoffmann-LaRoche & Co AG, issued 15 January 1932

F. Hoffmann-La Roche AG, commonly known as Roche (/rɒʃ/), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue[6] and the leading provider of cancer treatments globally.[7][8] In 2023, the company’s seat in Forbes Global 2000 was 76.[9]

The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021. Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year.

F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations.[10]47°33′31″N 7°36′22″E﻿ / ﻿47.558624°N 7.606018°E﻿ / 47.558624; 7.606018

## History

[edit]

Roche logo (1967–2021)

Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives.[11] In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories.[12] They also moved all their Jewish employees to the United States to save them from Nazi attention.[13]

In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members).[14] It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects.

In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington. By the early 1990s, Roche Biomedical became one of the largest clinical laboratory networks in the United States, with 20 major laboratories and US$600 million in sales.[15]

Roche has also produced various HIV tests and antiretroviral drugs. It bought the patents for the polymerase chain reaction (PCR) technique in 1992. In 1995, the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman LaRoche's HIV protease inhibitor, saquinavir. Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000.[16] On 28 April 1995, Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings).[17] Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002.

Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead tiered royalties of 14–22% of annual net sales without adjusting the payments for manufacturing costs, as had been allowed in the original licensing agreement.[18]

On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir.[19]

Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia.[20][21][22]

On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion.[23] On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp.[24]

On 26 March 2009, Roche acquired Genentech for $46.8 billion.[25] On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990,[26] after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto–based research facilities to their campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco.[27] Genentech became a wholly owned subsidiary group of Roche on 25 March 2009.[28] Roche began vacating the NJ site in 2012, and sold it off in 2016.[29]

Roche acquired Medingo Ltd. in April 2010, for $160 million[30] and BioImagene, Inc. in August for $100 million.[31]

In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project.[32] In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.[33] In July 2010, Roche acquired mtm laboratories AG for up to 190 million EUR.[34] In October, Roche acquired Anadys Pharmaceuticals, Inc. for $230 million.[35] In December, Roche announced it would acquire Munich-based Verum Diagnostica GmbH, gaining entry to the fastest-growing field in the coagulation diagnostics market.[36]

On 26 June 2012, Roche announced the closure of the Nutley/Clifton campus, which was completed in 2013. The property is in the process of remediation.[37]

In July 2013, Roche Diagnostics acquired blood diagnostics company Constitution Medical Inc. for $220 million.[38] Later, in September, Genentech announced it would acquire Arrayit Corporation.[39]

On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million,[40] as well as the rights to an experimental drug (ORY-1001) from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments.[41] On 2 June, Roche announced its intention to acquire Genia Technologies Inc. for up to $350 million.[42] In August 2014, the company agreed to purchase Californian-based pharmaceutical firm InterMune for $8.3 billion, at $74 a share this represents a 38% premium over the final share closing price,[43][44] as well as Santaris Pharma A/S for $450 million.[45] In December 2014, the company acquired next-generation sequencing processing company Bina Technologies for an undisclosed sum[46] and Dutalys GmbH[47] a developer of next-generation anti-bodies.[47]

On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622).[48] In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA.[49]

In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business.[50] Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications.[51] In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments).[52]

In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments.[53]

In January 2017, the company acquired ForSight VISION4.[54] In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price.[55] In November Roche acquired Viewics, Inc.[56] In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business.[57]

In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion.[58][59] In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).[60] Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics.[61] In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis.[62]

In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient.[63] The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders.[64] A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics.[65] In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.[66][67]

In March 2020, the Roche Diagnostics division reached a significant milestone with the FDA-approval of its high-volume Sars-CoV-2 diagnostic test, capable of analysing 1,400-8,800 samples within 24h on the proprietary Cobas 6800/8800 molecular testing system.[68] In September, the business acquired Ireland-based Inflazome, for €380 million, gaining control of its NLRP3 inflammasome inhibitors.[69][70]

In March 2021, Roche announced it would acquire GenMark Diagnostics for $1.8 billion.[71][72] Under the terms of agreement, Genmark diagnostics will become a subsidiary and the principal operations will continue to remain in Carlsbad, California.[73] In September, the company announced it would acquire German biotech group, TIB Molbiol, enhancing its molecular diagnostics operations.[74]

In September 2022, Roche acquired Good Therapeutics at a cost of $250M for its PD1-regulated IL-2 receptor agonist program.[75][76]

In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.[77] In December 2023, Roche acquired Carmot Therapeutics, an anti-obesity drug developer, for $2.7 billion.[78]

In October 2023, Monte Rosa Therapeutics and Roche signed a strategic cooperation and licensing agreement for the discovery and development of molecular adhesive degradators (MGD) to combat cancer and neurological diseases. The partnership includes Monte Rosa’s QuEENT discovery engine and Roche Holding expertise. Also Monte Rosa will receive $50m as an upfront payment and additional payments that will depend on the pre-clinical, clinical, commercial stages and sales, as well as multi-level royalty system and may exceed $2 billion.[79]

In March 2024, it was announced Roche had sold Genentech's site in Vacaville, California to the Swiss pharmaceutical company, Lonza for $1.2 billion.[80]

In November 2024, Roche acquired Poseida Therapeutics for US $1.0 billion.[81][82]

In April 2025, Roche announced it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs.[83]

## Family

[edit]

The Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families.[84] Many members of the family don't carry the last name Hoffmann anymore. Some are known as Oeri, Michalski, Faber-Castell, Fabre, Schmid or Duschmalé.[85]

### Acquisition history

[edit]

Roche acquisitions

* Hoffmann-La Roche (Founded 1896 by Fritz Hoffmann-La Roche)
* Biomedical Reference Laboratories (Acq 1982, restructured into Roche Biomedical Laboratories, Inc in 1982, sold 1995)
* Syntex (Acq 1994)
* Chugai Pharmaceuticals (Acq 2002)
* 454 Life Sciences (Acq 2007)
* Roche Diagnostics
* Spring BioScience Corp (Acq 2007)
* Ventana Medical Systems (Acq 2009)
* mySugr GmbH (Acq 2017)
* Viewics, Inc (Acq 2017)
* Flatiron Health (Acq 2018)
* Stratos Genomics (Acq 2020)
* Memory Pharmaceuticals Corp (Acq 2009)
* Genentech, Inc. (Acq 2009)
* Tanox, Inc (Acq 2006)
* Arrayit Corporation (Acq 2013)
* Seragon Pharmaceuticals, Inc. (Acq 2014)
* Jecure Therapeutics (Acq 2018)
* Medingo Ltd (Acq 2010)
* BioImagene, Inc. (Acq 2010)
* PVT Probenverteiltechnik GmbH (Acq 2010)
* MTM laboratories AG (Acq 2010)
* Anadys Pharmaceuticals, Inc. (Acq 2010)
* Verum Diagnostica GmbH (Acq 2011)
* Constitution Medical Inc. (Acq 2012)
* IQuum (Acq 2014)
* Genia Technologies Inc. (Acq 2014)
* InterMune (Acq 2014)
* Santaris Pharma A/S (Acq 2014)
* Bina Technologies, Inc. (Acq 2014)
* Dutalys GmbH (Acq 2014)
* Ariosa Diagnostics (Acq 2014)
* Trophos (Acq 2015)
* CAPP Medical (Acq 2015)
* GeneWEAVE BioSciences, Inc. (Acq 2015)
* Kapa Biosystems, Inc. (Acq 2015)
* Adheron Therapeutics (Acq 2015)
* Tensha Therapeutics (Acq 2016)
* ForSight VISION4 (Acq 2017)
* Ignyta Inc (Acq 2017)
* Foundation Medicine, Inc.  (Acq 2018)
* Tusk Therapeutics (Acq 2018)
* Spark Therapeutics (Acq 2019)
* Promedior (Acq 2019)
* Stratos Genomics (Acq 2020)
* Inflazome (Acq 2020)
* GenMark Diagnostics (Acq 2021)
* TIB Molbiol (Acq 2021)
* Good Therapeutics (Acq 2022)[86]
* Telavant (Acq 2023)[87]
* Carmot Therapeutics (Acq 2023)

## Financial data

[edit]

Financial data in CHF billions[88][89][90] Year  | 2013  | 2014  | 2015  | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024

|
|
|
|
|
|
|
|
|
|
|
|

Revenue | 46.780  | 47.462  | 48.145  | 50.576  | 53.299  | 56.846  | 63.751  | 58.323  | 62.801  | 66.43  | 60.44  | 62.39
Net Income | 11.164  | 9.332  | 8.863  | 9.576  | 8.633  | 10.865  | 14.108  | 15.068  | 14.935  | 13.53  | 12.36  | 9.19
Assets | 62.167  | 75.641  | 75.763  | 76.819  | 76.676  | 78.517  | 83.091  | 86.138  | 92.317  | 88.15  | 90.47  | 101.80
Employees  | 85,080  | 88,509  | 91,747  | 94,052  | 93,734  | 94,442  | 97,735  | 101,238  | 100,920  | 103,613  | 103,605  | 103,249

## Divisions

[edit]

Roche Holding AG is organized into two primary business divisions that reflect its dual focus on pharmaceutical development and diagnostic solutions. The company's divisional structure has evolved significantly since its founding in 1896, with major organizational changes occurring through strategic acquisitions and internal restructuring to create a comprehensive healthcare portfolio.[91]

Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.[92] All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.

### Organizational structure

[edit]

Roche operates under a divisional organizational structure led by a Chief Executive Officer who oversees the company's two main business divisions: Roche Pharmaceuticals and Roche Diagnostics. This structure mirrors the divisional organizational type commonly adopted by leading multinational corporations to manage complex operations across multiple business segments. The executive leadership includes specialized C-level executives responsible for Finance & Information, Pharma Research & Early Development (pRED), Pharma Partnering, and Group Communications.[93][94]

### Roche Pharmaceuticals

[edit]

The Pharmaceuticals Division represents Roche's core drug development and manufacturing operations, focusing on translating scientific excellence into effective medicines for patients. The division combines research capabilities across multiple global locations with clinical development, manufacturing, and commercial operations. Roche Pharmaceuticals maintains a broad-based portfolio that positions the company as one of the world's leading providers of clinically differentiated medicines.[95]

#### Genentech integration

[edit]

A critical component of the Pharmaceuticals Division is Genentech, Roche's biotechnology subsidiary based in South San Francisco, California. Genentech operates as a member of the Roche Group while maintaining its distinct identity and operational focus on breakthrough biotechnology research. The integration of Genentech has been fundamental to Roche's pharmaceutical strategy, providing specialized expertise in biotechnology and access to the North American market. Genentech has been operating for over 35 years and plays a pivotal role in Roche's pharmaceutical innovation.[96]

#### Chugai Pharmaceutical partnership

[edit]

The Pharmaceuticals Division also encompasses Roche's strategic alliance with Chugai Pharmaceutical Co., Ltd. in Japan. This partnership, established in the 1990s, created a research-driven pharmaceutical enterprise that serves as Roche's primary operational base in Japan. The Chugai alliance was the first instance of Roche building localized pharmaceutical capabilities in key global markets while maintaining integration with the broader Roche pharmaceutical network.[97]

#### Research and Development Network (RDN)

[edit]

The Pharmaceuticals Division operates through a global network of innovation engines designed to discover and develop breakthrough treatments. These research facilities are strategically located worldwide and function as independent innovation centers while maintaining coordination with central pharmaceutical operations. In 2024, the division entered into more than 70 new partnerships and managed over 250 alliances worldwide, demonstrating the scale and collaborative nature of Roche's pharmaceutical research approach.[98]

### Roche Diagnostics

[edit]

The Diagnostics Division focuses on developing high-quality and reliable diagnostic solutions and services that address the prevention, screening, diagnosis, and monitoring of diseases. This division has established Roche as a world leader in in-vitro diagnostics and represents a significant portion of the company's global operations. The division's comprehensive approach encompasses various testing methodologies and serves healthcare providers across multiple medical specialties.[99]

The main operational center for Roche Professional Diagnostics is located in Rotkreuz, Switzerland, which serves as a central hub for the division's European and global operations.[100]

#### Business Areas

[edit]

The Diagnostics Division is internally organized into five major business areas that reflect different aspects of diagnostic medicine and laboratory operations. These areas include Roche Applied Science, which focuses on research and applied diagnostic technologies; Roche Professional Diagnostics, which serves clinical laboratory needs; Roche Diabetes Care, specializing in diabetes monitoring and management solutions; Roche Molecular Diagnostics, concentrating on genetic and molecular testing; and Roche Tissue Diagnostics through the Ventana subsidiary, which provides tissue-based diagnostic solutions for pathology applications.[101]

## Products

[edit]

This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources in this section. Unsourced material may be challenged and removed. (January 2020) (Learn how and when to remove this message)

|

Hoffmann-La Roche develops drugs used for cancer treatment, against virus diseases and for treatment of metabolic diseases. The company is the world's largest spender in pharmaceutical R&D.[102]

Tamiflu box

Drugs produced by Roche include:[needs update][original research?][citation needed]

* Accutane/RoAccutane (isotretinoin), for severe (nodular) acne vulgaris - no longer sold under Accutane brand name (sold only in Canada) but is still available as RoAccutane, other brand names and Isotretinoin generics.[103]
* Actemra/RoActemra (tocilizumab), for rheumatoid arthritis.
* Actimmune (interferon gamma), for chronic granulomatous disease, later sold to Connetics Corporation, then InterMune, after that Vidara Therapeutics and finally Horizon Pharma as of 2019.
* Activase (alteplase), for heart attacks.
* Akynzeo (netupitant/palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
* Alecensa (alectinib), for ALK-positive non-small cell lung cancer.
* Aloxi (palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
* Anexate (flumazenil), for the reversal of acute benzodiazepine effects.
* Aurorix (moclobemide), for depression.
* Avastin (bevacizumab), for certain malignant tumours.
* Bactrim (trimethoprim/sulfamethoxazole), a sulphonamide antibacterial.
* Boniva Bonviva (ibandronic acid), for the treatment of osteoporosis in postmenopausal females.
* Camleed (enprostil), for gastric ulcer prevention.
* Cardene (nicardipine), for treatment of stable angina pectoris.
* Cathflo Activase (alteplase), for heart attacks.
* Cellcept (mycophenolate mofetil), for transplant rejection.
* Cotellic (cobimetinib), for melanoma.
* Cymevene (ganciclovir), for cytomegalovirus infection.
* Dalmane Dalmadorm (flurazepam), for insomnia.
* Dilatrend (carvedilol), for hypertension and congestive heart failure.
* Dormicum (midazolam), for insomnia and procedural sedation and analgesia.
* Erivedge (vismodegib), for basal-cell carcinoma.
* Esbriet (pirfenidone), for idiopathic pulmonary fibrosis.
* Fansidar (sulfadoxine/pyrimethamine), for malaria and toxoplasmosis.
* Fuzeon (enfuvirtide), for salvage therapy of HIV-1 infection.
* Gazyva (obinutuzumab), for chronic lymphocytic leukaemia.
* Hemlibra (emicizumab), for haemophilia A.
* Herceptin (trastuzumab), for HER-2 positive breast cancer.
* Hivid (zalcitabine), for HIV-1 infection, later discontinued in 2006.
* Inhibace (cilazapril), for hypertension and congestive heart failure.
* Invirase (saquinavir), for HIV-1 infection.
* Kadcyla (trastuzumab emtansine), for HER-2 positive breast cancer.
* Klonopin Rivotril (clonazepam), for epilepsy and anxiety disorders.
* Kytril (granisetron), for chemotherapy-induced nausea and vomiting, licensed by GlaxoSmithKline.
* Lariam (mefloquine), for malaria (both prevention and treatment).
* Lexotanil (bromazepam), for anxiety disorders.
* Librax (Chlordiazepoxide/clidinium bromide), treating stomach ulcers, irritable bowel syndrome, or symptoms related to intestinal infection.
* Librium (chlordiazepoxide), for anxiety disorders.
* Lucentis (ranibizumab), for wet age-related macular degeneration (AMD).
* Luxturna (voretigene neparvovec), for Leber's congenital amaurosis.
* MabThera (rituximab), for B-cell chronic lymphocytic leukaemia (and other haematological malignancies), non-Hodgkin lymphomas and rheumatoid arthritis.
* Madopar/Prolopa ([[levodopa benserazide), for Parkinson's disease.
* Mircera (methoxy polyethylene glycol-epoetin beta), for anaemia associated with chronic kidney disease.
* Naprosyn (naproxen), a NSAID used for pain relief and arthritis treatment.
* Neulastim (pegfilgrastim), for neutropaenia.
* Neupogen (filgrastim), for neutropaenia.
* Nutropin (somatropin), for growth hormone deficiency.
* Nutropin AQ (somatropin), for growth hormone deficiency.
* Nutropin Depot (somatropin), for growth hormone deficiency, later discontinued in 2004 and replaced by Nutropin AQ.
* Ocrevus (ocrelizumab), for MS.
* Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for hepatitis B and C.
* Perjeta (pertuzumab), for HER-2 positive breast cancer.
* Polatuzumab vedotin|Polivy (polatuzumab vedotin), for diffuse large B-cell lymphoma.
* Protropin (somatrem), for growth hormone deficiency, later discontinued in 2004 in favor of its successor, Nutropin.
* Pulmozyme (dornase alfa), for the improvement of pulmonary function in cystic fibrosis.
* Raptiva (efalizumab), for psoriasis, later withdrawn in 2009 due to the risk of PML.
* Recormon NeoRecormon (epoetin beta), for anaemia.
* Rituxan (rituximab), for non-Hodgkin's lymphoma.
* Rocaltrol (calcitriol), for osteoporosis and hypocalcaemia.
* Rocephin (ceftriaxone), a broad-spectrum cephalosporin antibiotic.
* Roferon A (peginterferon alfa-2a), for some haematological malignancies (hairy cell leukaemia, chronic myelogenous leukaemia), certain solid tumours (including Kaposi's sarcoma), genital warts and chronic hepatitis C.
* Rohypnol (flunitrazepam), for severe insomnia.
* Rozlytrek (entrectinib), for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumours.
* Soriatane/Neotigason (acitretin), for psoriasis.
* Tamiflu (oseltamivir), for influenza A and B (both treatment and prevention).
* Tarceva (erlotinib), for various cancers.
* Tasmar (tolcapone), for parkinson's disease, licensed by Mylan and Bausch Health.
* Tecentriq (atezolizumab), for non-small cell lung cancer.
* TNKase (tenecteplase), for heart attacks.
* Toradol (ketorolac), for pain management.
* Valcyte (valganciclovir), for cytomegalovirus infection.
* Valium (diazepam), for anxiety disorders, alcohol withdrawal, status epilepticus and other conditions.
* midazolam|Versed (midazolam), for insomnia and procedural sedation and analgesia.
* Vesanoid (tretinoin), for acute promyelocytic leukaemia.
* Viracept (nelfinavir), for HIV-1 infection, licensed by Pfizer and ViiV Healthcare.
* Xeloda (capecitabine), for breast and colorectal cancer.
* Xenical (orlistat), for obesity.
* Xofluza (baloxavir marboxil), for influenza A and B (both treatment and prevention).
* Xolair (omalizumab), for asthma, chronic idiopathic urticaria (CIU), and nasal polyps.[104]
* Zelboraf (vemurafenib), for late-stage V600E BRAF mutation-positive melanoma.
* Zenapax (daclizumab), for the prevention of acute transplant rejection.

Diabetes management products under the Accu-Chek brand include blood glucose meter, test strips and insulin pumps, as well as diabetes management software.

Other products include:

* Cobas Mira

## Price-fixing conspiracy

[edit]

See also: Cartel

Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in price fixing and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure — an offence under Swiss law — and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide.[105]

In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally. Hoffmann-La Roche paid $500 million in criminal fines to the United States.[105][106][107]

## Drug pricing issue and exit in the Swiss market

[edit]

In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG).[108] The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available.[109] Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs.[108]

When Swissmedic extended the temporary authorization in February 2025 due to still-missing complete clinical data from Phase III studies, Roche rejected the previously negotiated pricing model and demanded higher prices.[108][109] The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies and demanding additional efficacy evidence despite the drug showing positive effects in Phase II studies.[109] According to Swissmedic pricing data, a single 60-mg dose (two vials) of Lunsumio costs over 7,000 Swiss francs.[109]

The withdrawal was announced to oncologists on July 1, 2025, affecting approximately 24 patients annually who suffer from follicular lymphoma—a slowly progressing cancer of the lymph nodes with about 500 new cases per year in Switzerland.[108][109] Roche also refused to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations. Instead, the company offered to provide the medication free through its patient access program for hardship cases, though this option was described as much more restrictive.[108][109]

Oncologists criticized the decision as unprecedented, with Dr. Carmen de Ramon Ortiz of Geneva University Hospital noting that about 20% of follicular lymphoma patients require intensive treatment and that Lunsumio represents "a very innovative immunotherapy that stimulates the immune system, leading to high remission rates."[109] Industry experts characterized the withdrawal as a form of healthcare rationing and a "canary in the coal mine," noting that only half of EU-approved medications are available in Switzerland.[110] Some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms and trade uncertainties that could affect Roche's largest market, including potential tariff increases on pharmaceutical exports from 10% to up to 31%.[108][111]

The case was viewed by analysts as a potential precedent-setting "regulatory showdown" that could influence pharmaceutical pricing negotiations across the industry, particularly for rare disease treatments affecting small patient populations.[112]

## Controversies

[edit]

During the Second World War, Roche was reported to have collaborated with the Nazi regime in Germany and used prisoners-of-war or foreign forced labour in its German and Polish-based factories.[12]

In 2008 the Association of the British Pharmaceutical Industry (ABPI) suspended Roche for six months for breaching their code of conduct.[113]

In 2013, Roche had to pay back SFr 3.2 billion to the Swiss tax authorities due to transfer mispricing.[citation needed]

## Collaborative research

[edit]

In addition to internal research and development activities F. Hoffmann-La Roche is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[114][115] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of the European Federation of Pharmaceutical Industries and Associations and the European Commission.[116]

## See also

[edit]

* List of pharmaceutical companies
* Pharmaceutical industry in Switzerland

## References

[edit]

1. ^ "FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug". BioPharm International. UBM. 19 April 2018. Archived from the original on 20 June 2018. Retrieved 20 April 2018.
2. ^ "Executive Committee". Roche.com. F. Hoffmann-La Roche. Archived from the original on 18 April 2023. Retrieved 18 April 2023.
3. ^ "Roche names new head of $13 billion diagnostics unit". Reuters. 12 December 2022. Archived from the original on 18 April 2023. Retrieved 18 April 2023.
4. ^ "Finance Report 2021" (PDF). Roche Holding. 4 February 2024. Retrieved 24 August 2024.
5. ^ "Finance Report 2024" (PDF). Roche Holding. 3 February 2025. Retrieved 3 February 2025.
6. ^ McGlauflin, Paige (15 August 2022). "The world's 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021". Fortune. Archived from the original on 17 August 2022.
7. ^ "Top 10 Oncology Pharma Companies in the World | Market Research Blog". Market Research Reports® Inc. 17 May 2019. Archived from the original on 27 September 2022. Retrieved 18 October 2020.
8. ^ "Top 20 pharma companies by oncology sales - Top Pharma List". pmlive.com. 16 June 2014. Archived from the original on 21 August 2023. Retrieved 18 October 2020.
9. ^ "The Global 2000 2023". Forbes. Archived from the original on 29 January 2024. Retrieved 7 February 2024.
10. ^ "The Pharmaceutical Industry in Figures – 2008 Edition". European Federation of Pharmaceutical Industries and Associations. p. 49\. Archived from the original on 16 September 2008. Retrieved 25 August 2008.
11. ^ "Switzerland's Biggest Family Fortune Has Prospered for 124 Years". Bloomberg.com. 6 August 2020. Retrieved 16 March 2022.
12. ^ a b "Chemical firms exploited Nazi links, probe found". 30 August 2001. Archived from the original on 6 February 2022. Retrieved 6 February 2022.
13. ^ Leo Sternbach, 97; Invented Valium, Many Other Drugs by THOMAS H. MAUGH II OCT. 1, 2005 L.A. Times
14. ^ HannahBlake (1 November 2012). "A history of Roche". pharmaphorum.com. Archived from the original on 25 April 2022. Retrieved 16 March 2022.
15. ^ "Roche Biomedical Laboratories, Inc". FundingUniverse.com. Archived from the original on 22 January 2012. Retrieved 3 September 2007.
16. ^ "HIV Surveillance 
 United States, 1981—2008". Archived from the original on 9 November 2013. Retrieved 8 November 2013.
17. ^ Laboratory Corp of America Holdings · 10-Q · For 3/31/95 Archived 21 September 2020 at the Wayback Machine, SECInfo.com, Filed On 5/15/95, SEC File 1-11353, Accession Number 920148-95-11
18. ^ "Roche, Gilead End Tamiflu Feud". Red Herring. 16 November 2005. Archived from the original on 1 August 2020. Retrieved 5 April 2006.
19. ^ Kher, Unmesh (19 October 2005). "Why Roche Released Tamiflu". Time. Archived from the original on 22 October 2005. Retrieved 22 May 2008.
20. ^ "Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research". roche.com. Archived from the original on 5 February 2015. Retrieved 29 April 2015.
21. ^ Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after... by Dr. Joël Jean-Mairet. Brussels, March 31, 2011
22. ^ Cameron, F; McCormack, PL (January 2014). "Obinutuzumab: first global approval". Drugs. 74 (1): 147–54\. doi:10.1007/s40265-013-0167-3. PMID 24338113. S2CID 40983655.
23. ^ "Roche buys Ventana". Archived from the original on 5 June 2014. Retrieved 2 June 2014.
24. ^ Pollack, Andrew (12 March 2009). "Roche buys Memory Pharmaceuticals". The New York Times. Archived from the original on 6 August 2015. Retrieved 2 June 2014.
25. ^ Pollack, Andrew (12 March 2009). "Roche buys Genentech". The New York Times. Archived from the original on 6 August 2015. Retrieved 2 June 2014.
26. ^ Pollack, Andrew (5 February 1990). "Genentech-Roche Deal May Spur Similar Ties". The New York Times. Archived from the original on 4 September 2020. Retrieved 11 April 2009.
27. ^ Bawden, Tom (13 March 2009). "Roche swallows Genentech in third large drugs deal". The Times. London. Archived from the original on 12 June 2011. Retrieved 11 April 2009.
28. ^ Jucca, Lisa; Cage, Sam (26 March 2009). "Roche completes Genentech buy". Reuters. Archived from the original on 13 February 2023. Retrieved 11 April 2009.
29. ^ Proctor, Owen (17 June 2017). "Ex-Roche campus reinvented as 'On3' science center". northjersey.com. Retrieved 30 August 2022.
30. ^ "Roche buys Medingo". Archived from the original on 12 January 2014. Retrieved 2 June 2014.
31. ^ "Roche buysBioImagene". Archived from the original on 5 June 2014. Retrieved 2 June 2014.
32. ^ "2011 Facility of the Year Category winners". Archived from the original on 29 April 2014. Retrieved 28 June 2012.
33. ^ "Roche buys PVT". Archived from the original on 5 June 2014. Retrieved 2 June 2014.
34. ^ "Roche buys mtm labs". Archived from the original on 5 June 2014. Retrieved 2 June 2014.
35. ^ "Roche buys Anadys". Archived from the original on 5 June 2014. Retrieved 2 June 2014.
36. ^ "Roche Acquires Verum Diagnostica GmbH for €11 Million". BioSpace. Archived from the original on 13 February 2023. Retrieved 25 February 2019.
37. ^ "Roche announces closure of Nutley, NJ site". Archived from the original on 18 May 2013. Retrieved 28 June 2012.
38. ^ "Roche buys Constitution Medical". Archived from the original on 2 June 2014. Retrieved 2 June 2014.
39. ^ "Genentech Purchases Arrayit Corporation Technology". BioSpace. Archived from the original on 13 February 2023. Retrieved 25 February 2019.
40. ^ "Roche buys IQuum". Archived from the original on 2 June 2014. Retrieved 2 June 2014.
41. ^ Copley, Caroline (7 April 2014). "Roche buys experimental drug rights from Oryson". Reuters. Retrieved 2 June 2014.
42. ^ Mulier, Thomas (2 June 2014). "Roche buys Genia". Bloomberg. Archived from the original on 31 October 2014. Retrieved 2 June 2014.
43. ^ Michelle Cortez (24 August 2014). "Roche Holding Agrees to Buy InterMune for $8.3 Billion". Bloomberg L.P. Archived from the original on 23 January 2015. Retrieved 7 March 2017.
44. ^ "Roche pays 37% premium on shares for InterMune in US $8.3bn deal". San Francisco News.Net. 24 August 2014. Archived from the original on 26 August 2014. Retrieved 24 August 2014.
45. ^ "Roche Bags Santaris Pharma A/S In Deal Worth $450 Million". BioSpace. Archived from the original on 22 September 2022. Retrieved 25 February 2019.
46. ^ "Roche Acquires Big Data Platform Provider". GEN. 19 December 2014. Archived from the original on 25 December 2014. Retrieved 20 December 2014.
47. ^ a b "Roche To Pay Up To $489 Million For Next-Gen Antibody Firm Dutalys". BioSpace. 19 December 2014. Archived from the original on 26 February 2019. Retrieved 28 November 2018.
48. ^ "Roche to Buy Trophos for Up-to-$543M". GEN. 16 January 2015. Archived from the original on 18 January 2015. Retrieved 16 January 2015.
49. ^ "Roche Grabs CAPP Medical, a "Liquid Biopsy" Startup Targeting Cancer". BioSpace. Archived from the original on 26 February 2019. Retrieved 25 February 2019.
50. ^ "Roche to Acquire GeneWEAVE for Up-to $425M". GEN. 13 August 2015. Archived from the original on 15 August 2015. Retrieved 14 August 2015.
51. ^ "Roche Acquires Genomic Tools Provider Kapa Biosystems". GEN. 19 August 2015. Archived from the original on 21 August 2015. Retrieved 19 August 2015.
52. ^ "Roche to Acquire Adheron Therapeutics for $105 Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business". GEN. 9 October 2015. Archived from the original on 19 March 2017. Retrieved 23 May 2017.
53. ^ "Roche Acquires Tensha Therapeutics for $115M Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". GEN. 11 January 2016. Archived from the original on 5 November 2016. Retrieved 23 May 2017.
54. ^ "ForSight VISION4, Inc. Announces Acquisition by Roche" (Press release). PR Newswire.
55. ^ Miller, John (30 June 2017). "Roche buys diabetes app firm in digital health push". Reuters. Archived from the original on 30 June 2017.
56. ^ "Roche Scoops Up Bay Area's Viewics Amid Diagnostic Data Push". BioSpace. Archived from the original on 22 September 2022. Retrieved 25 February 2019.
57. ^ "Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion". Reuters.com. Reuters. 22 December 2017. Archived from the original on 6 December 2018.
58. ^ Dye, Jessica (15 February 2018). "Roche pays $1.9bn for Alphabet-backed Flatiron Health". Financial Times. Archived from the original on 10 December 2022.
59. ^ "Roche to buy Flatiron Health for $1.9 billion to expand cancer care..." Reuters.com. Reuters. 15 February 2018. Archived from the original on 9 December 2018.
60. ^ "Roche pays $2.4 billion for rest of cancer expert Foundation Medicine". Reuters.com. Reuters. 19 June 2018. Archived from the original on 9 December 2018.
61. ^ "Roche Acquires Cancer Immunotherapy Developer Tusk Therapeutics". 28 September 2018. Archived from the original on 26 February 2019. Retrieved 25 February 2019.
62. ^ "Roche buys U.S. biotech Jecure in race for liver disease drugs". Reuters.com. Reuters. 27 November 2018. Archived from the original on 28 November 2018.
63. ^ "Roche 'steps up' for gene therapy with $4.3 billion Spark bet". Reuters.com. Reuters. 25 February 2019. Archived from the original on 25 February 2019.
64. ^ "Roche says its $4.3 billion offer for Spark is still on track for June completion". CNBC. 3 April 2019. Archived from the original on 10 April 2019. Retrieved 10 April 2019.
65. ^ Koltrowitz, Silke; Nadeem, Dania (23 December 2019). "Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal". Reuters. Archived from the original on 23 December 2019. Retrieved 24 December 2019.
66. ^ "Roche to Acquire Fibrosis-Focused Promedior for up to $1.4 Billion". 15 November 2019.
67. ^ "Promedior Enters into Definitive Merger Agreement to be Acquired by Roche". 15 November 2019.
68. ^ Hale C. (March 2020). "FDA grants Roche coronavirus test emergency green light within 24 hours" Archived 14 March 2020 at the Wayback Machine FierceBiotech. Retrieved 13 March 2020.
69. ^ "Roche Dives into NLRP3 Inflammasome Inhibition with Acquisition of Inflazome". BioSpace. 21 September 2020. Archived from the original on 8 October 2020. Retrieved 22 September 2020.
70. ^ "Inflazome Announces Acquisition by Roche". BioSpace. Archived from the original on 22 September 2022. Retrieved 3 January 2021.
71. ^ "Roche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMark". 15 March 2021. Archived from the original on 25 April 2022. Retrieved 15 March 2021.
72. ^ "Roche buys GenMark for $1.8 million to challenge test rivals". Reuters. 15 March 2021. Archived from the original on 13 February 2023.
73. ^ "Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample". Archived from the original on 28 April 2021. Retrieved 2 May 2021.
74. ^ "Roche Holding to buy TIB Molbiol to enhance molecular diagnostics". Reuters. 9 September 2021.
75. ^ "Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche". www.businesswire.com. 7 September 2022. Archived from the original on 17 July 2023. Retrieved 17 July 2023.
76. ^ Garde, Damian (7 September 2022). "Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy". STAT. Archived from the original on 17 July 2023. Retrieved 17 July 2023.
77. ^ "Roche Signs $2.8 Billion Alnylam Deal for Hypertension Drug". Bloomberg.com. 24 July 2023. Retrieved 25 July 2023.
78. ^ "Roche enters obesity market with Carmot takeover but drugs may not be available until 2030". CNBC. 4 December 2023. Retrieved 8 December 2023.
79. ^ "Monte Rosa and Roche partner for development of MGDs". Pharmaceutical Technology. 18 October 2023. Archived from the original on 28 October 2023. Retrieved 27 February 2024.
80. ^ "Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile". pharmafile.com. 20 March 2024. Retrieved 20 March 2024.
81. ^ "Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies". www.roche.com. Retrieved 26 November 2024.
82. ^ "Roche to buy cell therapy developer Poseida for $1B". BioPharma Dive. Retrieved 26 November 2024.
83. ^ Smolak, Helena. "Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom". WSJ. Retrieved 22 April 2025.
84. ^ "Switzerland's Biggest Family Fortune Has Prospered for 124 Years". Bloomberg.com. 6 August 2020. Archived from the original on 10 September 2021. Retrieved 15 April 2022.
85. ^ "Nachkomme und Verwaltungsrat Jörg Duschmalé: "Roche war immer da, seit ich ganz klein war"". 18 September 2021. Archived from the original on 9 July 2022. Retrieved 9 July 2022.
86. ^ "Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche". Businesswire. September 2022. Retrieved 17 July 2023.
87. ^ Burger, Ludwig; Revill, John (23 October 2023). "Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal". Reuters. Archived from the original on 1 November 2023. Retrieved 13 March 2024.
88. ^ "Roche Holding Bilanz, Gewinn und Umsatz | Roche Holding Geschäftsbericht | 855167". wallstreet-online.de. Archived from the original on 5 November 2018. Retrieved 5 November 2018.
89. ^ MarketScreener. "ROCHE HOLDING AG : Financial Data Forecasts Estimates and Expectations | ROG | CH0012032048 | MarketScreener". www.marketscreener.com. Retrieved 3 June 2020.
90. ^ GmbH, finanzen net. "Roche Financials | Markets Insider". Business Insider. Archived from the original on 3 June 2020. Retrieved 3 June 2020.
91. ^ "Roche's Organizational Structure". Organimi. Retrieved 3 July 2024.
92. ^ "Financial Report 2021" (PDF). Roche Holding. 4 February 2022. Archived (PDF) from the original on 23 February 2022. Retrieved 5 April 2022.
93. ^ "Roche Leadership Structure". Organimi. Retrieved 3 July 2024.
94. ^ "Strategy Study: How Roche Grew Through Research & Development". Cascade Strategy Factory. Retrieved 25 July 2025.
95. ^ "Roche Pharmaceuticals". Roche.
96. ^ "Genentech About Us". Genentech.
97. ^ "Our History". Roche.
98. ^ "Genentech Partnerships". BIO International Convention.
99. ^ "Diagnostic Solutions". Roche Diagnostics.
100. ^ "Roche Locations". Roche.
101. ^ "Roche Diagnostics Business Areas". Roche Diagnostics.
102. ^ Miller, John (19 December 2017). "Roche touts Swiss-led R&D unit after years in Genentech's shadow". Reuters. Archived from the original on 19 December 2017. Retrieved 19 December 2017.
103. ^ "Roche stops selling acne drug Accutane". Reuters. 26 June 2009. Retrieved 23 February 2016.
104. ^ "FDA approves Xolair® (omalizumab) for adults with nasal polyps". www.roche.com. Archived from the original on 7 October 2023. Retrieved 21 September 2023.
105. ^ a b Mathiason, Nick (25 November 2001). "Blowing the final whistle". The Observer. Retrieved 30 September 2014.
106. ^ Corporate Crime Reporter. Corporate Crime Reporter. Retrieved 2013-11-24.
107. ^ "Cartel price announcements: The vitamins industry" (PDF). International Journal of Industrial Organization. 26. 2008. Archived from the original (PDF) on 20 August 2016.
108. ^ a b c d e f Peterhans, Anielle; Boss, Catherine. "Roche zieht Krebsmedikament zurück: «Der Kampf ums Geld wird auf dem Rücken schwer kranker Menschen ausgetragen»". Tages-Anzeiger (in German). Retrieved 25 July 2025.
109. ^ a b c d e f g "BAG-Streit: Roche zieht Krebsmedikament Lunsumio zurück". SRF (in German). Retrieved 25 July 2025.
110. ^ "Roche vs. BAG – der Kanarienvogel in der Mine". Handelszeitung (in German). Retrieved 25 July 2025.
111. ^ "Roche hat mit vielen Unsicherheiten zu kämpfen". Nau.ch (in German). Retrieved 25 July 2025.
112. ^ "Roche Aktie: Regulatorischer Showdown!". Börse Express (in German). Retrieved 25 July 2025.
113. ^ "Roche is suspended from ABPI for "actions likely to bring discredit" on the industry" (PDF). BJM.
114. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460\. pp. 221–238\. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
115. ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
116. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.

## Further reading

[edit]

* Hans Conrad Peyer (1996) Roche – A Company History 1896–1996  Basel: Editiones Roche ISBN 3-907770-59-5

## External links

[edit]

Wikimedia Commons has media related to Hoffmann-La Roche.

* Official website
* Roche on OpenSecrets, a website that tracks and publishes data on campaign finance and lobbying

* v
* t
* e

Pharmaceutical companies of Switzerland

* Actelion
* Alcon
* Alliance Boots
* Basilea Pharmaceutica
* Cilag
* Debiopharm
* Fenjal
* Ferring Pharmaceuticals
* Galderma
* Health Valley
* Lonza
* Molecular Partners
* Novartis
* Nycomed
* Octapharma
* Relief Therapeutics
* Roche
* Straumann

* v
* t
* e

Swiss Market Index companies of Switzerland

* ABB
* Alcon
* Geberit
* Givaudan
* Holcim
* Kühne + Nagel
* Logitech
* Lonza
* Nestlé
* Novartis
* Partners Group
* Richemont
* Roche
* Sika
* Sonova
* Swiss Life
* Swiss Re
* Swisscom
* UBS
* Zurich Insurance Group

* v
* t
* e

Swiss Leader Index companies of Switzerland

* ABB
* Adecco
* ams
* Alcon
* Geberit
* Givaudan
* Holcim
* Julius Bär
* Kuehne + Nagel
* Lindt (PS)
* Logitech
* Lonza
* Nestlé
* Novartis
* Partners Group
* Richemont
* Roche
* Schindler
* SGS
* Sika
* Sonova
* Straumann
* Swatch Group
* Swiss Life
* Swiss Re
* Swisscom
* Temenos
* UBS
* VAT Group
* Zurich Insurance Group

* v
* t
* e

SMI MID (SMIM) companies of Switzerland

* Adecco
* ams
* Avolta
* Bâloise
* Barry Callebaut
* Belimo
* BKW Energie
* Clariant
* Ems-Chemie
* Flughafen Zürich
* Galenica
* Georg Fischer
* Julius Bär
* Helvetia
* Lindt & Sprüngli
* Meyer Burger
* PSP Swiss Property
* Roche (bearer shares)
* Sandoz
* Schindler
* SIG Combibloc
* SGS AG
* Straumann
* Swatch Group
* Swiss Prime Site
* Tecan
* Temenos
* VAT Group

* v
* t
* e

DJSI World companies

Americas|

* Abbott Laboratories
* AbbVie
* Adobe
* Agilent Technologies
* Alphabet
* American Airlines Group
* Autodesk
* Banco Bradesco
* Banco do Brasil
* Bancolombia
* Biogen
* Canadian National
* CPKC
* Cisco
* Companhia Energética de Minas Gerais - CEMIG
* Cummins
* CVS Health Corporation
* DaVita
* Dow
* eBay
* Ecolab
* Edwards Lifesciences Corporation
* Elevance Health
* Palabella
* Fortinet
* General Mills
* Gilead Sciences
* Grupo Argos
* Grupo Sura
* Grupo Nutresa
* Healthpeak Properties
* Hess Corporation
* Hilton Worldwide
* Host Hotels & Resorts
* HP
* Illumina, Inc.
* Ingersoll Rand
* Itaú Unibanco
* Itaúsa
* Jacobs Solutions
* Kinross Gold Corporation
* Klabin
* Las Vegas Sands
* Lockheed Martin
* Lojas Renner
* Medtronic
* Microsoft
* Mondelez International
* Moody's Corporation
* Newmont
* Northrop Grumman
* Oshkosh Corporation
* Owens Corning
* Philip Morris International
* Prologis
* Regeneron Pharmaceuticals
* Republic Services
* Rumo Logística
* S&P Global
* Salesforce
* ServiceNow
* Snap Inc
* Sociedad Química y Minera
* Spirit AeroSystems
* Teck Resources
* The Cigna Group
* Gap Inc.
* The Williams Companies
* Union Pacific Corporation
* UnitedHealth Group
* Waste Management, Inc.
* Whirlpool Corporation

Europe|

* Aberdeen Group
* Acciona
* AENA
* Allianz
* Alstom
* Amadeus IT Group
* Anglo American plc
* Arkema
* ASML Holding
* ASR Nederland
* Assicurazioni Generali S.p.A.
* Aviva
* Axa
* Banco Bilbao Vizcaya Argentaria
* Banco Santander
* Bankinter
* Billerud
* bioMérieux
* BNP Paribas SA
* Bureau Veritas
* CaixaBank
* Carrefour SA
* Castellum
* CNH Industrial
* Coca-Cola HBC
* Covivio
* Dassault Systèmes
* Deutsche Börse
* Deutsche Post
* Deutsche Telekom
* Diageo
* EDP Group
* Enagás
* Endesa
* Enel SpA
* Engie
* EQT
* Exxaro
* Ferrovial
* Galp Energia
* GEA Group
* Gold Fields
* Grifols
* GSK
* H&M
* Hera Group
* Hochtief
* Hugo Boss
* Iberdrola
* Indra Sistemas
* Inditex
* Infineon Technologies
* Informa
* International Distributions Services
* Intesa Sanpaolo
* Italgas
* Iveco
* Kering
* Kesko Oyj
* Ahold Delhaize
* Landsec
* Lanxess
* Leonardo (company)
* Linde
* Merlin Properties
* Metro
* Moncler
* Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft
* Neste Oyj
* Nexi
* NN Group
* OMV Aktiengesellschaft
* Partners Group
* Pearson
* Pirelli
* Poste Italiane
* PostNL
* Prysmian
* Publicis Groupe
* Randstad NV
* Reckitt Benckiser Group
* Red Eléctrica Corporación
* Relx
* Rexel
* Roche
* Rolls-Royce Holdings
* Saipem
* Sanofi
* SAP
* Schneider Electric
* SGS
* Siemens Aktiengesellschaft
* Signify
* Snam
* Sodexo
* Sonova
* STMicroelectronics
* Storebrand
* Temenos AG
* Terna Group
* TF1
* TotalEnergies
* Trane Technologies
* UBS Group
* United Utilities
* UPM-Kymmene Oyj
* Valmet Oyj
* Veolia
* Vestas Wind Systems
* Viaplay Group
* Warehouses De Pauw
* Wendel
* WH Smith
* Worldline SA

Asia Pacific|

* Advanced Info Service
* Advantech Co
* Airports of Thailand Public Company Limited
* Ajinomoto Co., Inc.
* ANA Holdings
* ANZ Bank
* ASE Group
* Bangkok Dusit Medical Services
* Brambles Limited
* Bridgestone
* CapitaLand
* Cathay United Bank
* Central Pattana
* Central Retail Corporation
* Chailease Holding Company
* Chang Hwa Bank
* KGI Financial Holding
* Chugai Pharmaceutical Co.
* Chunghwa Telecom Co., Ltd.
* CP All
* CTBC Financial Holding
* Delta Electronics (Thailand) Public Company Limited
* Delta Electronics, Inc.
* Dentsu
* Dexus
* Doosan Enerbility
* Dr. Reddy's Laboratories Limited
* E Ink
* E.SUN Commercial Bank
* Far EasTone
* First Financial
* Fortescue (company)
* Fubon Financial Holding Co., Ltd.
* Fujitsu
* GPT Group
* Hana Financial Group Inc.
* Hindalco Industries
* Honda
* Hyundai Engineering & Construction
* Hyundai Glovis
* Hyundai Mobis
* Hyundai Motor Company
* Hyundai Steel
* Indorama Ventures Public Company Limited
* InnoLux Corporation
* ITOCHU Corporation
* JD.com
* JSW Steel
* Kakao Corp.
* Kanzhun Limited
* Kasikornbank
* KB Financial Group
* Keppel Corporation Limited
* Kia Corporation
* Komatsu Limited
* LG Electronics
* LG Household & Health Care
* Link Real Estate Investment Trust
* Lite-On
* Lixil Group
* LY Corporation
* Mahindra & Mahindra Limited
* Marui
* Mega International Commercial Bank
* Meiji Holdings
* Mirae Asset Securities
* Mitsubishi Chemical Group
* Mitsubishi Heavy Industries
* Mitsui & Co
* Nabtesco Corporation
* Nanya Technology Corporation
* National Australia Bank Limited
* Nikon Corporation
* Nippon Prologis
* Nissin Foods
* Nomura Holdings
* Nomura Research Institute
* NTT Data
* Olympus Corporation
* OMRON Corporation
* Ono Pharmaceutical
* Petronas
* President Chain Store Corporation
* PTT Exploration and Production
* PTT Global Chemical
* PTT Public Company
* Ricoh
* Samsung Biologics
* Samsung C&T Corporation
* Samsung Electro-Mechanics
* Samsung SDI
* Samsung Securities
* Sands China
* Siam Commercial Bank
* Sekisui Chemical
* Sekisui House
* Seven & I Holdings
* Shin Kong Group
* Shinhan Financial Group
* Shiseido
* Siam Cement Group
* Bank SinoPac
* SK Inc.
* SK Telecom
* SoftBank Corporation
* S-Oil
* Sojitz Corporation
* Stockland
* Sumitomo Forestry
* Swire Properties
* Sysmex Corporation
* TS Financial Holdings
* Taiwan Cooperative Bank
* Taiwan Mobile
* Taiwan Semiconductor Manufacturing Company
* Tech Mahindra
* Tencent Holdings
* ThaiBev
* Shanghai Commercial and Savings Bank
* Toppan
* Toto
* Transurban
* United Microelectronics Corporation
* UPL Limited
* Vanguard International Semiconductor Corporation
* Vedanta Limited
* Vicinity Centres
* Wilmar International
* WIN Semiconductors
* Woodside Energy
* WuXi AppTec
* WuXi Biologics
* Yokogawa Electric Corporation
* Yuanta Securities
* Yum China Holdings

Portals:

* Companies
* Switzerland

Authority control databases

International|

* ISNI
* VIAF

National|

* Germany
* United States
* Czech Republic
* 2
* Israel

Other|

* IdRef
* Historical Dictionary of Switzerland
* Yale LUX

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template